M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Findings show growing optimism across the pharma sector as dealmaking accelerates, innovation strengthens, and companies adapt to tariffs, pricing reforms, and looming patent expirations
The union minister spoke at the 2nd Pharma Summit & Awards 2026 organised by ASSOCHAM in New Delhi
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
